Back

Discrimination of atrial fibrillation burden using clinical and cardiac imaging data

1 April 2025 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Clinical perspective on atrial fibrillation care Arrhythmias EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Mr Andreas Ugo Gasser

Cardiovascular Research Institute Basel, Basel (Switzerland)

5 More presentations in this session

Presentation thumbnail
Safety and efficacy of dronedarone in overweight and obesity: a post-hoc analysis of the ATHENA trial
Associate Professor M. Vamos (Szeged, HU)
Abstract Slides Video
Presentation thumbnail
Obstructive sleep apnea phenotypes associated with atrial fibrillation
Doctor M. Van den Broek (Eindhoven, NL)
Abstract Slides Video
Presentation thumbnail
The acute clinical effects of rhythm control on elderly patients with long-standing atrial fibrillation, severe tricuspid regurgitation, and right heart failure: a multicenter prospective cohort study
Doctor F. Besiroglu (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
longest AF episode duration: a new indicator of AF burden?
Ms E. Schuijt (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Impact of right or left sided radiation therapy for breast cancer in patients with atrial fibrillation on procedural findings and follow-up results of RF-catheter ablation
Doctor M. Tydecks (Munich, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Clinical perspective on atrial fibrillation care

The Event

Event poster

EHRA 2025

1 April 2025 13:30 CET
You may be interested in
thumbnail
Congress Presentation
Clinical implications of atrial fibrillation recurrence vs. burden following catheter ablation: outcome data from 3 contemporary clinical trials using an insertable cardiac monitor
thumbnail
Congress Presentation
Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials
thumbnail
Congress Presentation
Atrial fibrillation burden as efficacy endpoint for atrial fibrillation ablation: strengths and weaknesses of implementation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources